Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 20/20 | 0.44 |
| ▸ | MMP3 | P08254 | 2/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5409857 | 0.83 | BMP1 (0.58) | BMP1MMP3PDE4APDE4BPDE4C | |
| SCHEMBL5406823 | 0.83 | BMP1 (0.48) | BMP1MMP3MMP1MMP13 | |
| SCHEMBL5404225 | 0.83 | BMP1 (0.62) | BMP1MMP3MMP1MMP13 | |
| SCHEMBL5411995 | 0.81 | BMP1 (0.52) | BMP1MMP3PDE4APDE4BPDE4C | |
| SCHEMBL5411018 | 0.81 | BMP1 (0.61) | BMP1MMP3MMP1MMP13 | |
| SCHEMBL5398123 | 0.80 | BMP1 (0.63) | BMP1MMP3MMP1MMP13 | |
| SCHEMBL5408313 | 0.80 | BMP1 (0.65) | BMP1MMP3MMP1MMP13 | |
| SCHEMBL5412067 | 0.79 | BMP1 (0.64) | BMP1MMP3MMP1MMP13 | |
| SCHEMBL5405379 | 0.79 | BMP1 (0.64) | BMP1MMP3MMP1MMP13 | |
| SCHEMBL5408612 | 0.79 | BMP1 (0.62) | BMP1MMP3MMP1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1373264-B1 | 3-HETEROCYCLYLPROPANOHYDROXAMIC ACID AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LTD (GB) | 2004-12-22 | — | — | EP | disclosed |
| US-6821972-B2 | ANTISCARRING AGENTS; WOUND HEALING AGENTS; ENZYME INHIBITORS | PFIZER INC. | 2004-11-23 | — | — | US | disclosed |
| EP-1373264-A1 | 3-HETEROCYCLYLPROPANOHYDROXAMIC ACID AS PROCOLLAGEN C-PROTEINASE INHIBITORS | Pfizer Limited (GB) | 2004-01-02 | — | — | EP | disclosed |
| US-20030069291-A1 | 3-heterocyclylpropanohydroxamic acid PCP inhibitors | PFIZER INC. | 2003-04-10 | — | — | US | disclosed |
| WO-2002079200-A1 | 3-HETEROCYCLYLPROPANOHYDROXAMIC ACID AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LIMITED (GB) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069291-A1 | 3-heterocyclylpropanohydroxamic acid PCP inhibitors | PAH, CYP2F1, CYP7A1 | BMP1 449/4885MMP3 3194/4885PDE4A 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.